Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Revenues 

Microsoft Excel

Revenues as Reported

Gilead Sciences Inc., income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
HIV 18,175 17,194 16,315 16,938 16,438
Cell Therapy 1,869 1,459 871 607 456
Trodelvy 1,063 680 380 49
Oncology 2,932 2,139 1,251 656 456
Chronic hepatitis C virus (HCV) 1,767 1,810 1,881 2,064 2,936
Chronic hepatitis B virus (HBV)/Chronic hepatitis delta virus (HDV) 1,017 988 969 860 742
Liver Disease 2,784 2,798 2,850 2,924 3,678
Veklury 2,184 3,905 5,565 2,811
Other 859 946 1,027 1,026 1,547
Product sales 26,934 26,982 27,008 24,355 22,119

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Product sales Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Gilead Sciences Inc. product sales decreased from 2021 to 2022 and from 2022 to 2023.